Related Experiment Video
Updated: Apr 19, 2026

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
Published on: July 3, 2025
Adverse Event Reporting Patterns Associated with Degarelix and Relugolix: A Pharmacovigilance Study Based on the
Jun Luo1, Zehui Rao2, Kun Zhou1
1Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Introduction:
Degarelix and relugolix are two GnRH antagonists approved by the FDA for androgen deprivation therapy in the treatment of prostate cancer. However, differences in their safety profiles and the characteristics of specific adverse events (AEs) remain insufficiently characterized.
Methods:
This study analyzes AEs associated with degarelix and relugolix reported in the FAERS from Q1 2009 through Q2 2024. Multiple signal detection methods, including reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and empirical Bayes geometric mean, were employed to assess drug-AE associations.
Results:
A total of 3,357 AE reports associated with degarelix and 4,075 reports related to relugolix were retrieved from the FAERS database. Signal analysis revealed that the most common AEs associated with degarelix were injection site reactions, whereas relugolix was frequently associated with hot flushes. Furthermore, the study identified several rare AEs not included in the drug labeling.
Conclusion:
This study identified common AEs associated with degarelix and relugolix but also identified several potential safety signals. These findings provide additional pharmacovigilance evidence for post-marketing safety monitoring and highlight potential safety signals that warrant further clinical and epidemiological investigation.
More Related Videos
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drug Regulation
Therapeutic Drug Monitoring: Affecting Factors
FDA Approved Drugs: Changes to Approved Drugs
Modified-Release Drug Delivery Systems: Overview